Resultats de la cerca - Andrew R. Pettitt

Refinar resultats
  1. 1
    Mechanism of action of purine analogues in chronic lymphocytic leukaemia

    Mechanism of action of purine analogues in chronic lymphocytic leukaemia per Andrew R. Pettitt

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication

    Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication per Jonathan P Evans, Sue Ziébland, Andrew R. Pettitt

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Relationship between p53 dysfunction, CD38 expression, andIgVH mutation in chronic lymphocytic leukemia

    Relationship between p53 dysfunction, CD38 expression, andIgVH mutation in chronic lymphocytic leukemia per Ke Lin, Paul D. Sherrington, Michael Dennis, Zoltán Mátrai, John C. Cawley, Andrew R. Pettitt

    Publicat 2002
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative toTP53 mutation

    p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative toTP53 mutation per Andrew R. Pettitt, Paul D. Sherrington, Grant S. Stewart, John C. Cawley, A. Malcolm R. Taylor, Tatjana Stanković

    Publicat 2001
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia

    CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia per Zoltán Mátrai, Ke Lin, Michael Dennis, Paul D. Sherrington, Mirko Zuzel, Andrew R. Pettitt, John C. Cawley

    Publicat 2001
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Deletion of 17p in cancers: Guilt by (p53) association

    Deletion of 17p in cancers: Guilt by (p53) association per Francisca van Kampen, Abigail Clark, Jamie Soul, Aditi Kanhere, Mark Glenn, Andrew R. Pettitt, Nagesh Kalakonda, Joseph R. Slupsky

    Publicat 2025
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

    Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition per Jianguo Zhuang, Sarah Hawkins, A.M. Glenn, Ke Lin, Glenda G. Johnson, A. Carter, John C. Cawley, Andrew R. Pettitt

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia

    Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia per David Oscier, Claire Dearden, Efrem Eren, Chris Fegan, George Follows, Peter Hillmen, Tim Illidge, Estella Matutes, Don Milligan, Andrew R. Pettitt, Anna Schuh, J. Z. Wimperis

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ

    Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ per Waseem Al-Jameel, Gou Xiao-jun, Xi Jin, Jiacheng Zhang, Qiang Wei, Jianzhong Ai, Hong Li, Asmaa M. S. Al-Bayati, Angela Platt‐Higgins, Andrew R. Pettitt, Philip S. Rudland, Youqiang Ke

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244

    Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISR... per Peter Hoskin, Lisa Lowry, Alan Horwich, Andrew Jack, Ben Mead, Barry W. Hancock, Paul Smith, Wendi Qian, Philippa Patrick, Bilyana Popova, Andrew R. Pettitt, David Cunningham, Ruth Pettengell, John Sweetenham, David C. Linch, Peter Johnson

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia

    Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia per Samantha J.L. Knight, Christopher Yau, Ruth Clifford, Adele Timbs, Elham Sadighi Akha, Hélène Dreau, Adam Burns, Cristian Ciria, David Oscier, Andrew R. Pettitt, Susan Dutton, Chris Holmes, Jenny C. Taylor, Jean‐Baptiste Cazier, Anna Schuh

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

    Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study per Peter Hillmen, John G. Gribben, George Follows, Donald Milligan, Hazem A. Sayala, Paul Moreton, David Oscier, Claire Dearden, Daniel B. Kennedy, Andrew R. Pettitt, Amit Nathwani, Abraham Varghese, D. Cohen, Andy C. Rawstron, Stephan Oertel, Christopher Pocock

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

    Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome per Stephen Robinson, Anna Sureda, Carmen Canals, N. Russell, Dolores Caballero, Almalina Bacigalupo, A Iriondo, Gordon Cook, Andrew R. Pettitt, Gèrard Socié, Francesca Bonifazi, Alberto Bosi, M. Michallet, Effie Liakopoulou, J. Maertens, Jakob Passweg, Fiona Clarke, Rodrigo Martino, Norbert Schmitz

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia

    DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia per Elaine Willmore, Sarah L. Elliott, Tryfonia Mainou‐Fowler, Geoffrey Summerfield, Graham Jackson, Fran O'Neill, Christopher J. Lowe, Anthony Carter, Robert J. Harris, Andrew R. Pettitt, Céline Cano, Roger J. Griffin, Ian G. Cowell, Caroline A. Austin, Barbara W. Durkacz

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

    Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study per Peter Hillmen, Andy C. Rawstron, Kristian Brock, S Munoz-Vicente, Francesca Yates, Rebecca Bishop, Rebecca H. Boucher, Donald Macdonald, Chris Fegan, Alison M. McCaig, Anna Schuh, Andrew R. Pettitt, John G. Gribben, Piers Patten, Stephen Devereux, Adrian Bloor, Christopher P. Fox, Francesco Forconi, Talha Munir

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

    Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution per Ronjon Chakraverty, Guillermo Ortí, Sy Ha, Jun Shen, Adele K. Fielding, Panagiotis Kottaridis, Donald Milligan, Matthew Collin, Charles Crawley, Peter Johnson, Andrew Clark, Anne Parker, Adrian Bloor, Ruth Pettengell, John A. Snowden, Andrew R. Pettitt, Richard E. Clark, G Hale, Karl S. Peggs, Kirsty Thomson, Emma Morris, Stephen Mackinnon

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    <scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome

    <scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome per Toby A. Eyre, Ruth Clifford, Adrian Bloor, Lucy Boyle, Corran Roberts, Maité Cabes, Graham P. Collins, Stephen Devereux, George Follows, Christopher P. Fox, John G. Gribben, Peter Hillmen, Chris S.R Hatton, Tim Littlewood, Helen O. McCarthy, J. A. H. Murray, Andrew R. Pettitt, Elizabeth J. Soilleux, Basile Stamatopoulos, Sharon Love, Andrew Wotherspoon, Anna Schuh

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia per Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

    Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL per Romain Guièze, Pauline Robbe, Ruth Clifford, Sophie de Guibert, Bruno Pereira, Adele Timbs, Marie‐Sarah Dilhuydy, Maité Cabes, Loïc Ysebaert, Adam Burns, Florence Nguyen‐Khac, Frédéric Davi, Lauren Véronèse, Patricia Combes, Magali Le Garff‐Tavernier, Véronique Leblond, Hélène Merle‐Béral, Reem Alsolami, Angela Hamblin, Joanne Mason, Andrew R. Pettitt, Peter Hillmen, Jenny C. Taylor, Samantha J.L. Knight, Olivier Tournilhac, Anna Schuh

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

    DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma per Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna, Scott A. Tetreault, Sarit Assouline, Jiřı́ Mayer, Michele Merli, Scott D. Lunin, Andrew R. Pettitt, Zoltán Nagy, Olivier Tournilhac, Karem-Etienne Abou-Nassar, Michael Crump, Eric D. Jacobsen, Sven de Vos, Virginia Kelly, Weiliang Shi, Lori Steelman, NgocDiep Le, David T. Weaver, Stephanie Lustgarten, Nina D. Wagner‐Johnston, Pier Luigi Zinzani

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: